Clofarabine

證據等級: L5

預測適應症: 10 個

Clofarabine: From Acute Lymphoblastic Leukemia to Myeloid Leukemia

One-Sentence Summary

Clofarabine is a purine nucleoside antimetabolite historically used for relapsed/refractory paediatric acute lymphoblastic leukaemia (ALL). The TxGNN model predicts it may also be effective for Myeloid Leukemia, with 50 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Relapsed/refractory paediatric acute lymphoblastic leukaemia (ALL) — approved in other markets (e.g., US FDA, 2004); no German marketing authorization on record
Predicted New Indication	Myeloid Leukemia
TxGNN Prediction Score	99.88%
Evidence Level	L2
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed proprietary mechanism-of-action data (DrugBank field) is currently unavailable (data gap DG002). Based on the literature evidence collected for this candidate, clofarabine is a second-generation purine nucleoside analog designed to combine the favourable properties of cladribine and fludarabine. It acts through three main mechanisms: inhibition of ribonucleotide reductase, inhibition of DNA polymerase (blocking DNA synthesis and repair), and disruption of mitochondrial membrane integrity leading to apoptosis (see PMID 17852710, PMID 22957815).

Clofarabine's proven efficacy is in relapsed/refractory paediatric acute lymphoblastic leukaemia (ALL), where it received accelerated FDA approval in 2004. ALL and myeloid leukaemia (AML) are both aggressive haematologic malignancies driven by uncontrolled clonal proliferation of blast cells in the bone marrow, and both are treated with DNA-damaging cytotoxic backbones (cytarabine, anthracyclines, alkylators). Because clofarabine's anti-leukaemic action is independent of lymphoid- versus myeloid-lineage specificity — it targets the DNA replication machinery common to all rapidly dividing blasts — its mechanistic rationale extends naturally from ALL to AML.

This is further supported by extensive real-world use: clofarabine has already been studied in dozens of AML-focused trials (single-agent, combination with cytarabine/idarubicin/mitoxantrone, and as conditioning for allogeneic stem cell transplantation), including a completed randomized Phase II trial (CLARA vs. HDAC, n=735) and a completed multicentre randomized Phase III trial in childhood AML (AML08), reinforcing that the TxGNN prediction reflects an indication area with substantial pre-existing clinical investigation rather than a purely speculative signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02665065	Phase 3	Active, not recruiting	153	Pivotal trial of Iomab-B with reduced-intensity conditioning (incl. clofarabine-containing regimens) vs. conventional care in relapsed/refractory AML
NCT00454480	Phase 2/3	Completed	2000	Large treatment-development programme for older AML/high-risk MDS patients evaluating multiple chemotherapy combinations
NCT00932412	Phase 2	Completed	735	Randomized trial: Clofarabine/intermediate-dose cytarabine (CLARA) vs. high-dose cytarabine (HDAC) as consolidation in newly-diagnosed AML
NCT00067028	Phase 2	Completed	116	Randomized comparison of Clofarabine+Ara-C vs. Clofarabine+Idarubicin vs. triple combination in relapsed/refractory AML, high-grade MDS, and CML blast phase
NCT00373529	Phase 2	Completed	116	Single-agent clofarabine efficacy in elderly untreated AML patients unlikely to benefit from intensive induction
NCT01295307	Phase 2	Completed	86	Clofarabine salvage therapy in relapsed/refractory AML as bridge to allogeneic HCT
NCT02686593	Phase 2	Completed	50	CLAM (clofarabine, cytarabine, mitoxantrone) as first salvage regimen for relapsed/refractory AML
NCT01101880	Phase 2	Completed	50	Clofarabine + high-dose cytarabine + G-CSF priming in newly diagnosed AML/advanced MDS/MPN
NCT00044889	Phase 2	Completed	40	Open-label study of clofarabine monotherapy in adult refractory/relapsed AML
NCT00299156	Phase 2	Completed	65	Oral clofarabine weekly dosing in myelodysplastic syndrome (MDS), a myeloid precursor condition

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31246522	2019	RCT (Phase III)	J Clin Oncol	AML08 multicentre randomized Phase III trial: clofarabine can replace anthracyclines/etoposide in remission induction for childhood AML
18565853	2008	RCT	Blood	Randomized study of clofarabine vs. clofarabine+low-dose cytarabine as front-line therapy in patients ≥60 with AML/high-risk MDS
32187883	2020	Phase 2 study	Cancer Medicine	Clofarabine+cytarabine+mitoxantrone (CLAM) shows high response rates and effective bridge to allo-HCT in refractory/relapsed AML
22957815	2013	Review	Leukemia & Lymphoma	Comprehensive review of clofarabine's role in AML treatment
25457773	2015	Review	Crit Rev Oncol Hematol	Review of clofarabine's role in adult AML treatment, monotherapy and combination strategies
17852710	2007	Review	Leukemia & Lymphoma	"Clofarabine: past, present, and future" — mechanism and synergy with other chemotherapeutics
19852733	2009	Review	Future Oncology	Review of clofarabine for adult AML, favourable single-agent activity vs. standard agents
31637757	2020	Phase 1/2 trial	Am J Hematol	Multisite trial of optimally dosed clofarabine + low-dose TBI as non-myeloablative conditioning for AML transplant
29773602	2018	Phase 1B trial	Haematologica	Clofarabine + high-dose cytarabine + liposomal daunorubicin in paediatric relapsed/refractory AML
31905904	2019	Translational study	Cancers	Clofarabine-based consolidation improves relapse-free survival in AML with micro-complex karyotype

Germany Market Information

Clofarabine currently holds no marketing authorization in Germany (BfArM records: 0 licenses, market status "not marketed").

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (purine nucleoside analog / antimetabolite)
Myelosuppression Risk	High — as a DNA synthesis/ribonucleotide reductase inhibitor, clofarabine consistently causes significant neutropenia, thrombocytopenia, and anaemia across the dose-finding and toxicity-focused trials in this evidence pack
Emetogenicity Classification	Moderate to high, consistent with other purine nucleoside analogs used in leukaemia induction regimens
Monitoring Items	CBC with differential, liver and renal function, electrolytes (tumour lysis syndrome risk), signs of infection during neutropenic periods
Handling Protection	Must follow cytotoxic drug handling regulations (PPE, closed-system transfer devices)

Safety Considerations

Please refer to the package insert for safety information. Detailed TFDA/BfArM warnings, contraindications, and drug interaction data are not yet available for this candidate (data gap DG001, marked as a Blocking severity item that must be resolved before formal safety review, S1).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Clofarabine's antileukaemic activity in myeloid leukaemia is supported by an unusually deep evidence base — 50 clinical trials and 20 publications, including a completed randomized Phase 2 trial (CLARA vs. HDAC, n=735) and a completed multicentre randomized Phase III trial in childhood AML (AML08) — giving an evidence level of L2. However, the drug is not currently marketed in Germany, and formal safety labelling data is missing, so progression should proceed cautiously with explicit guardrails rather than as an unconditional "Go."

To proceed, the following is needed:

TFDA/BfArM package insert warnings and contraindications (resolve blocking data gap DG001)
Confirmed mechanism-of-action data via DrugBank API (resolve data gap DG002)
Assessment of the German/EU regulatory pathway for market entry, since clofarabine currently has zero authorizations in Germany
Clarification of the target AML subpopulation (age, cytogenetic risk, relapsed/refractory status) to align with the strongest existing trial evidence (e.g., CLARA regimen, older-patient front-line studies)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.